Evaluation of the Safety and Immunogenicity of the RTS,S/AS01(E) Malaria Candidate Vaccine When Integrated in the Expanded Program of Immunization


Agnandji, ST; Asante, KP; Lyimo, J; Vekemans, J; Soulanoudjingar, SS; Owusu, R; Shomari, M; Leach, A; Fernandes, J; Dosoo, D; Chikawe, M; Issifou, S; Osei-Kwakye, K; Lievens, M; Paricek, M; Apanga, S; Mwangoka, G; Okissi, B; Kwara, E; Minja, R; Lange, J; Boahen, O; Kayan, K; Adjei, G; Chandramohan, D; Jongert, E; Demoitie, MA; Dubois, MC; Carter, T; Vansadia, P; Villafana, T; Sillman, M; Savarese, B; Lapierre, D; Ballou, WR; Greenwood, B; Tanner, M; Cohen, J; Kremsner, PG; Lell, B; Owusu-Agyei, S; Abdulla, S; (2010) Evaluation of the Safety and Immunogenicity of the RTS,S/AS01(E) Malaria Candidate Vaccine When Integrated in the Expanded Program of Immunization. The Journal of infectious diseases, 202 (7). pp. 1076-1087. ISSN 0022-1899 DOI: 10.1086/656190

Full text not available from this repository.

Abstract

Background. The RTS,S/AS01(E) malaria candidate vaccine is being developed for immunization of African infants through the Expanded Program of Immunization (EPI). Methods. This phase 2, randomized, open, controlled trial conducted in Ghana, Tanzania, and Gabon evaluated the safety and immunogenicity of RTS,S/AS01(E) when coadministered with EPI vaccines. Five hundred eleven infants were randomized to receive RTS,S/AS01(E) at 0, 1, and 2 months (in 3 doses with diphtheria, tetanus, and whole-cell pertussis conjugate [DTPw]; hepatitis B [HepB]; Haemophilus influenzae type b [Hib]; and oral polio vaccine [OPV]), RTS,S/AS01(E) at 0, 1, and 7 months (2 doses with DTPwHepB/Hib+OPV and 1 dose with measles and yellow fever), or EPI vaccines only. s. The occurrences of serious adverse events were balanced across groups; none were vaccine-related. One child from the control group died. Mild to moderate fever and diaper dermatitis occurred more frequently in the RTS,S/AS01(E) coadministration groups. RTS,S/AS01(E) generated high anti-circumsporozoite protein and anti-hepatitis B surface antigen antibody levels. Regarding EPI vaccine responses upon coadministration when considering both immunization schedules, despite a tendency toward lower geometric mean titers to some EPI antigens, predefined noninferiority criteria were met for all EPI antigens except for polio 3 when EPI vaccines were given with RTS,S/AS01(E) at 0, 1, and 2 months. However, when antibody levels at screening were taken into account, the rates of response to polio 3 antigens were comparable between groups. Conclusion. RTS,S/AS01(E) integrated in the EPI showed a favorable safety and immunogenicity evaluation.

Item Type: Article
Keywords: HEPATITIS-B-VACCINE, VITAMIN-A SUPPLEMENTATION, RANDOMIZED-TRIAL, DOUBLE-BLIND, FALCIPARUM-MALARIA, CHILDREN, INFANTS, GABON, EPIDEMIOLOGY, MOZAMBIQUE, Bacterial Capsules, administration & dosage, adverse effects, immunology, Diphtheria-Tetanus-Pertussis Vaccine, administration & dosage, adverse effects, immunology, Female, Gabon, Ghana, Haemophilus Vaccines, administration & dosage, adverse effects, immunology, Hepatitis B Vaccines, administration & dosage, adverse effects, immunology, Humans, Immunization, methods, Immunization, Secondary, methods, Infant, Malaria Vaccines, administration & dosage, adverse effects, immunology, Male, Poliovirus Vaccine, Oral, administration & dosage, adverse effects, immunology, Tanzania
Faculty and Department: Faculty of Infectious and Tropical Diseases > Dept of Disease Control
Research Centre: Malaria Centre
Vaccine Centre
PubMed ID: 20735271
Web of Science ID: 281912100012
URI: http://researchonline.lshtm.ac.uk/id/eprint/2524

Statistics


Download activity - last 12 months
Downloads since deposit
0Downloads
332Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item